SEOUL (Reuters) - A South Korean drug maker is aiming to market a new anti-impotence drug in the United States, officials said on Friday, adding they hope it will be the first approved South Korean product of its kind for the U.S. market.
Dong-A Pharmaceutical Co. began South Korean sales this month of Zydena, the first South Korean-made anti-impotence drug to be approved by regulators in its home country.
Already a subscriber? Log in.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!